{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:32:16Z","timestamp":1790677936665,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002418","name":"Intel Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002418","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.intimp.2021.107904","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T09:54:36Z","timestamp":1624960476000},"page":"107904","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["The PI3K\u03b4 inhibitor parsaclisib ameliorates pathology and reduces autoantibody formation in preclinical models of systemic lupus erythematosus and Sj\u04e7gren\u2019s syndrome"],"prefix":"10.1016","volume":"98","author":[{"given":"Monika D.","family":"Scuron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany L.","family":"Fay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.intimp.2021.107904_b0005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0968-0004(97)01061-X","article-title":"Phosphoinositide 3-kinases: a conserved family of signal transducers","volume":"22","author":"Vanhaesebroeck","year":"1997","journal-title":"Trends Biochem. Sci."},{"issue":"Pt 3","key":"10.1016\/j.intimp.2021.107904_b0010","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1042\/bj3460561","article-title":"The PI3K-PDK1 connection: more than just a road to PKB","volume":"346","author":"Vanhaesebroeck","year":"2000","journal-title":"Biochem. J."},{"issue":"9","key":"10.1016\/j.intimp.2021.107904_b0015","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1073\/pnas.94.9.4330","article-title":"P110delta, a novel phosphoinositide 3-kinase in leukocytes","volume":"94","author":"Vanhaesebroeck","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"4","key":"10.1016\/j.intimp.2021.107904_b0020","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri1056","article-title":"PI3K in lymphocyte development, differentiation and activation","volume":"3","author":"Okkenhaug","year":"2003","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.intimp.2021.107904_b0025","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fimmu.2012.00256","article-title":"Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies","volume":"3","author":"Puri","year":"2012","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2021.107904_b0030","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.4049\/jimmunol.0900432","article-title":"Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses","volume":"183","author":"Durand","year":"2009","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2021.107904_b0035","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.4049\/jimmunol.178.4.2328","article-title":"Requirement for phosphoinositide 3-kinase p110delta signaling in B cell antigen receptor-mediated antigen presentation","volume":"178","author":"Al-Alwan","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2021.107904_b0040","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.coph.2015.05.017","article-title":"PI3K inhibitors in inflammation, autoimmunity and cancer","volume":"23","author":"Stark","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2021.107904_b0045","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/14737140.2017.1285702","article-title":"Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow","volume":"17","author":"Greenwell","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"6","key":"10.1016\/j.intimp.2021.107904_b0050","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.4049\/jimmunol.1500792","article-title":"B Cell-Specific MHC Class II Deletion Reveals Multiple Nonredundant Roles for B Cell Antigen Presentation in Murine Lupus","volume":"195","author":"Giles","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2021.107904_b0055","doi-asserted-by":"crossref","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.intimp.2021.107904_b0060","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fimmu.2014.00233","article-title":"Characterization of Novel PI3Kdelta Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies","volume":"5","author":"Haselmayer","year":"2014","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2021.107904_b0065","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1007\/s10753-014-9818-0","article-title":"Inhibition of PI3Kdelta improves systemic lupus in mice","volume":"37","author":"Wang","year":"2014","journal-title":"Inflammation"},{"issue":"2","key":"10.1016\/j.intimp.2021.107904_b0070","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/annrheumdis-2017-212619","article-title":"Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjogren's syndrome","volume":"78","author":"Nayar","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2021.107904_b0075","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jdsr.2019.09.006","article-title":"B cell dysregulation in primary Sjogren's syndrome: A review","volume":"55","author":"Ibrahem","year":"2019","journal-title":"Jpn. Dent. Sci. Rev."},{"issue":"7","key":"10.1016\/j.intimp.2021.107904_b0080","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.3390\/jcm9072299","article-title":"Current State of Knowledge on Primary Sjogren's Syndrome, an Autoimmune Exocrinopathy","volume":"9","author":"Parisis","year":"2020","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.intimp.2021.107904_b0085","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood-2005-07-3041","article-title":"Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells","volume":"107","author":"Bilancio","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.intimp.2021.107904_b0090","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1002\/eji.200838618","article-title":"B-cell responses to B-cell activation factor of the TNF family (BAFF) are impaired in the absence of PI3K delta","volume":"38","author":"Henley","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2021.107904_b0095","first-page":"247","article-title":"The epidemiology of Sjogren's syndrome","volume":"6","author":"Patel","year":"2014","journal-title":"Clin. Epidemiol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107904_b0100","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.4317\/medoral.20199","article-title":"Role of salivary anti-SSA\/B antibodies for diagnosing primary Sjogren's syndrome","volume":"20","author":"Wei","year":"2015","journal-title":"Med. Oral Patol. Oral Cir. Bucal."},{"issue":"2","key":"10.1016\/j.intimp.2021.107904_b0105","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/ard.62.2.168","article-title":"The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome","volume":"62","author":"Mariette","year":"2003","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2021.107904_b0110","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1124\/jpet.120.265538","article-title":"Parsaclisib Is a Next-Generation PI3Kdelta Inhibitor With Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy","volume":"374","author":"Shin","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"10","key":"10.1016\/j.intimp.2021.107904_b0115","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","volume":"56","author":"Coutre","year":"2015","journal-title":"Leuk. Lymphoma."},{"issue":"11","key":"10.1016\/j.intimp.2021.107904_b0120","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1021\/acsmedchemlett.9b00334","article-title":"INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kdelta)","volume":"10","author":"Yue","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.intimp.2021.107904_b0125","doi-asserted-by":"crossref","first-page":"e000078","DOI":"10.1136\/lupus-2014-000078","article-title":"Haematological manifestations of lupus","volume":"2","author":"Fayyaz","year":"2015","journal-title":"Lupus Sci. Med."},{"key":"10.1016\/j.intimp.2021.107904_b0130","unstructured":"National Research Council (U.S.). Committee for the Update of the Guide for the Care and Use of Laboratory Animals., Institute for Laboratory Animal Research (U.S.), and National Academies Press (U.S.), Guide for the care and use of laboratory animals. 2011, National Academies Press,: Washington, D.C. p. xxv, 220 p."},{"issue":"6","key":"10.1016\/j.intimp.2021.107904_b0135","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1172\/JCI78082","article-title":"Sexual dimorphism in autoimmunity","volume":"125","author":"Rubtsova","year":"2015","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.intimp.2021.107904_b0140","first-page":"58520","article-title":"Transdermal Measurement of Glomerular Filtration Rate in Mice","volume":"140","author":"Scarfe","year":"2018","journal-title":"J. Vis. Exp."},{"issue":"1","key":"10.1016\/j.intimp.2021.107904_b0145","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12882-016-0380-x","article-title":"Granulocyte colony-stimulating factor treatment ameliorates lupus nephritis through the expansion of regulatory T cells","volume":"17","author":"Yan","year":"2016","journal-title":"BMC Nephrol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107904_b0150","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1002\/cpph.65","article-title":"Spontaneous Model of Sjogren's Syndrome in NOD Mice","volume":"86","author":"Scuron","year":"2019","journal-title":"Curr. Protoc. Pharmacol."},{"key":"10.1016\/j.intimp.2021.107904_b0155","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-1-60761-849-2_4","article-title":"Histopathology procedures: from tissue sampling to histopathological evaluation","volume":"691","author":"Slaoui","year":"2011","journal-title":"Methods Mol. Biol."},{"issue":"9","key":"10.1016\/j.intimp.2021.107904_b0160","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1021\/acsmedchemlett.7b00293","article-title":"Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors","volume":"8","author":"Hoegenauer","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.intimp.2021.107904_b0165","doi-asserted-by":"crossref","first-page":"e20191336","DOI":"10.1084\/jem.20191336","article-title":"Activated PI3Kdelta breaches multiple B cell tolerance checkpoints and causes autoantibody production","volume":"217","author":"Lau","year":"2020","journal-title":"J. Exp. Med"},{"issue":"6","key":"10.1016\/j.intimp.2021.107904_b0170","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1172\/JCI78084","article-title":"Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity","volume":"125","author":"Suurmond","year":"2015","journal-title":"J. Clin. Invest"},{"issue":"3","key":"10.1016\/j.intimp.2021.107904_b0175","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.rdc.2016.03.002","article-title":"Autoantibodies in Sjogren's Syndrome","volume":"42","author":"Fayyaz","year":"2016","journal-title":"Rheum Dis. Clin. North Am."},{"issue":"10","key":"10.1016\/j.intimp.2021.107904_b0180","first-page":"21037","article-title":"Prognostic value of Sjogren's syndrome autoantibodies","volume":"3","author":"Scofield","year":"2018","journal-title":"J. Lab. Precis. Med."},{"key":"10.1016\/j.intimp.2021.107904_b0185","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fimmu.2017.00603","article-title":"Mechanisms of Autoantibody-Induced Pathology","volume":"8","author":"Ludwig","year":"2017","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107904_b0190","doi-asserted-by":"crossref","first-page":"e000199","DOI":"10.1136\/lupus-2016-000199","article-title":"Mouse models of lupus: what they tell us and what they don't","volume":"5","author":"Richard","year":"2018","journal-title":"Lupus Sci. Med."},{"issue":"18","key":"10.1016\/j.intimp.2021.107904_b0195","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.2174\/1381612821666150316115727","article-title":"Animal models of lupus and lupus nephritis","volume":"21","author":"Du","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.intimp.2021.107904_b0200","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3389\/fmed.2020.00316","article-title":"B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice","volume":"7","author":"Parodis","year":"2020","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.intimp.2021.107904_b0205","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3389\/fimmu.2013.00306","article-title":"IFNalpha Inducible Models of Murine SLE","volume":"4","author":"Liu","year":"2013","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2021.107904_b0210","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1745-7599.2002.tb00119.x","article-title":"National Kidney Foundation Guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"14","author":"Goolsby","year":"2002","journal-title":"J. Am. Acad. Nurse Pract."},{"issue":"7","key":"10.1016\/j.intimp.2021.107904_b0215","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.4049\/jimmunol.0902595","article-title":"Identification of new pathogenic players in lupus: autoantibody-secreting cells are present in nephritic kidneys of (NZBxNZW)F1 mice","volume":"184","author":"Lacotte","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2021.107904_b0220","doi-asserted-by":"crossref","first-page":"104417","DOI":"10.1016\/j.yrtph.2019.104417","article-title":"Next tier in vitro and in vivo nonclinical studies further elucidating the safety and toxicity profile of MB-102, a novel fluorescent tracer agent for measurement of glomerular filtration rate","volume":"107","author":"Dorshow","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107904_b0225","doi-asserted-by":"crossref","first-page":"544","DOI":"10.4049\/jimmunol.1400350","article-title":"Inhibition of PI3Kdelta reduces kidney infiltration by macrophages and ameliorates systemic lupus in the mouse","volume":"193","author":"Suarez-Fueyo","year":"2014","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107904_b0230","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/ndt\/gfq496","article-title":"The PI3K\/Akt\/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin","volume":"26","author":"Stylianou","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"issue":"3","key":"10.1016\/j.intimp.2021.107904_b0235","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.semnephrol.2010.03.003","article-title":"Macrophages and immunologic inflammation of the kidney","volume":"30","author":"Duffield","year":"2010","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.intimp.2021.107904_b0240","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.3389\/fimmu.2018.02043","article-title":"The Treatment of Activated PI3Kdelta Syndrome","volume":"9","author":"Coulter","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2021.107904_b0245","first-page":"209","article-title":"Animal models of Sjogren's syndrome: an update","volume":"37 Suppl 118(3)","author":"Xiao","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"issue":"9","key":"10.1016\/j.intimp.2021.107904_b0250","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1093\/rheumatology\/kev420","article-title":"Exploring BAFF: its expression, receptors and contribution to the immunopathogenesis of Sjogren's syndrome","volume":"55","author":"Thompson","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.intimp.2021.107904_b0255","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1124\/jpet.116.237347","article-title":"Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3Kdelta","volume":"361","author":"Allen","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2021.107904_b0260","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB Signaling: Navigating the Network","volume":"169","author":"Manning","year":"2017","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.intimp.2021.107904_b0265","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2174\/187153009788452417","article-title":"The AKT axis as a therapeutic target in autoimmune diseases","volume":"9","author":"Wu","year":"2009","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921005403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921005403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T11:26:23Z","timestamp":1747308383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921005403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":53,"alternative-id":["S1567576921005403"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107904","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The PI3K\u03b4 inhibitor parsaclisib ameliorates pathology and reduces autoantibody formation in preclinical models of systemic lupus erythematosus and Sj\u04e7gren\u2019s syndrome","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107904","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107904"}}